Literature DB >> 28358697

Assessment of Radiobiological α/β Ratio in Lung Cancer and Fibroblast Cell Lines Using Viability Assays.

Ilias V Karagounis1, Eleni K Skourti1, Maria V Liousia1, Michael I Koukourakis2.   

Abstract

BACKGROUND/AIM: Altered fractionation is an area of intense clinical research in radiation oncology. Estimation of the α/β ratio of individual carcinomas after establishment of primary cell cultures from tumor biopsies may prove of importance in the individualization of radiotherapy schemes.
MATERIALS AND METHODS: Here we proposed a simple method to estimate the α/β ratio in cultured cell lines (two lung carcinomas: A549 and H1299; one lung fibroblast cell line: MRC5), using viability assays.
RESULTS: For the A549 cell line, the α/β ratio ranged from 14-25 Gy, for H1299 from 11-43 Gy and for the MRC5 fibroblast cell line this was far lower, ranging from 0.69 to 6 Gy. The α/β ratio decreased when extracted from comparisons of lower dose per fraction schemes.
CONCLUSION: The α/β ratio of a cell line can be easily defined after simple viability/dose fractionation experiments. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung cancer cell lines; lung fibroblasts; α/β ratio

Mesh:

Year:  2017        PMID: 28358697      PMCID: PMC5411742          DOI: 10.21873/invivo.11042

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

1.  Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy.

Authors:  Alize E H Scheenstra; Maddalena M G Rossi; José S A Belderbos; Eugène M F Damen; Joos V Lebesque; Jan-Jakob Sonke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

2.  Establishment and validation of a method for multi-dose irradiation of cells in 96-well microplates.

Authors:  Ioannis Abatzoglou; Christos E Zois; Stamatia Pouliliou; Michael I Koukourakis
Journal:  Biochem Biophys Res Commun       Date:  2013-01-16       Impact factor: 3.575

3.  Evaluation of the alamarblue assay for adherent cell irradiation experiments.

Authors:  Maria A Zachari; Panagiota S Chondrou; Stamatia E Pouliliou; Achilleas G Mitrakas; Ioannis Abatzoglou; Christos E Zois; Michael I Koukourakis
Journal:  Dose Response       Date:  2013-09-12       Impact factor: 2.658

4.  A new fluorometric assay for cytotoxicity measurements in-vitro.

Authors:  B Page; M Page; C Noel
Journal:  Int J Oncol       Date:  1993-09       Impact factor: 5.650

Review 5.  The role of biologically effective dose (BED) in clinical oncology.

Authors:  B Jones; R G Dale; C Deehan; K I Hopkins; D A Morgan
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

6.  Is alpha/beta for prostate tumors really low?

Authors:  J Fowler; R Chappell; M Ritter
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

Review 7.  Radiation-induced cell death mechanisms.

Authors:  David Eriksson; Torgny Stigbrand
Journal:  Tumour Biol       Date:  2010-05-20

8.  Early and late effects of fractionated irradiation and the kinetics of repair in rat lung.

Authors:  E van Rongen; H T Madhuizen; C H Tan; S K Durham; M J Gijbels
Journal:  Radiother Oncol       Date:  1990-04       Impact factor: 6.280

9.  Relationship between early and late normal-tissue injury after postmastectomy radiotherapy.

Authors:  S M Bentzen; M Overgaard
Journal:  Radiother Oncol       Date:  1991-03       Impact factor: 6.280

Review 10.  What would be the most appropriate α/β ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer.

Authors:  Alexander Chi; Sijin Wen; Zhongxing Liao; Jack Fowler; Jiahong Xu; Nam P Nguyen; James S Welsh; Ritsuko Komaki
Journal:  Biomed Res Int       Date:  2013-11-20       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.